AU2002226371A1 - Oral extended release formulation of gepirone - Google Patents

Oral extended release formulation of gepirone

Info

Publication number
AU2002226371A1
AU2002226371A1 AU2002226371A AU2637102A AU2002226371A1 AU 2002226371 A1 AU2002226371 A1 AU 2002226371A1 AU 2002226371 A AU2002226371 A AU 2002226371A AU 2637102 A AU2637102 A AU 2637102A AU 2002226371 A1 AU2002226371 A1 AU 2002226371A1
Authority
AU
Australia
Prior art keywords
gepirone
amount
extended release
tablets
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002226371A
Other languages
English (en)
Inventor
Johannes Gerardus Joseph Egberink
John Francis Engelhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Publication of AU2002226371A1 publication Critical patent/AU2002226371A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002226371A 2000-12-08 2001-11-30 Oral extended release formulation of gepirone Abandoned AU2002226371A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00204388 2000-12-08
EP00204388 2000-12-08
PCT/EP2001/014189 WO2002045753A2 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone

Publications (1)

Publication Number Publication Date
AU2002226371A1 true AU2002226371A1 (en) 2002-06-18

Family

ID=8172397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002226371A Abandoned AU2002226371A1 (en) 2000-12-08 2001-11-30 Oral extended release formulation of gepirone

Country Status (19)

Country Link
EP (1) EP1343504A2 (hu)
JP (1) JP2004517083A (hu)
KR (1) KR20040018314A (hu)
CN (1) CN1479620A (hu)
AR (1) AR031461A1 (hu)
AU (1) AU2002226371A1 (hu)
BR (1) BR0115976A (hu)
CA (1) CA2436692A1 (hu)
CZ (1) CZ20031589A3 (hu)
EC (1) ECSP034627A (hu)
HU (1) HUP0401021A2 (hu)
IL (1) IL155855A0 (hu)
MX (1) MXPA03005099A (hu)
NO (1) NO20032581L (hu)
PL (1) PL362445A1 (hu)
RU (1) RU2003120446A (hu)
SK (1) SK6942003A3 (hu)
WO (1) WO2002045753A2 (hu)
ZA (1) ZA200303915B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545469A1 (en) * 2002-09-24 2005-06-29 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
BRPI0419179A (pt) * 2004-11-05 2007-12-18 Fabre Kramer Pharmaceuticals I formulação de alta dosagem de liberação prolongada de gepirona
MY198454A (en) * 2017-07-26 2023-08-29 Abbott Lab Nutritional Tablets and Methods of Making the Same
CN109745323A (zh) * 2017-11-01 2019-05-14 四川科瑞德制药股份有限公司 氮哌酮类化合物提高副交感神经活性的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form

Also Published As

Publication number Publication date
KR20040018314A (ko) 2004-03-03
AR031461A1 (es) 2003-09-24
NO20032581D0 (no) 2003-06-06
HUP0401021A2 (hu) 2004-09-28
EP1343504A2 (en) 2003-09-17
WO2002045753A2 (en) 2002-06-13
JP2004517083A (ja) 2004-06-10
ECSP034627A (es) 2004-09-28
CN1479620A (zh) 2004-03-03
SK6942003A3 (en) 2003-10-07
PL362445A1 (en) 2004-11-02
CZ20031589A3 (cs) 2003-11-12
ZA200303915B (en) 2004-08-20
RU2003120446A (ru) 2005-02-20
IL155855A0 (en) 2003-12-23
NO20032581L (no) 2003-06-06
MXPA03005099A (es) 2004-02-12
BR0115976A (pt) 2003-12-30
WO2002045753A3 (en) 2002-08-29
CA2436692A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
EP0914119B1 (en) Process for forming solid oral dosage forms of valsartan
EP1351668B1 (en) Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles
US6103263A (en) Delayed pulse release hydrogel matrix tablet
US20110071137A1 (en) Process for preparing sustained release tablets
US20110177168A1 (en) Composition
JP2638389B2 (ja) 経口投与後のインダパミドの徐放性マトリックス錠剤
KR100465895B1 (ko) 파라세타몰을 포함하는 경구용 정제
AU5748299A (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose derivative
KR20010015918A (ko) 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드
WO2006123213A1 (en) Modified release formulations of gliclazide
AU2002226371A1 (en) Oral extended release formulation of gepirone
US11878078B2 (en) Instant release pharmaceutical preparation of anticoagulant and preparation method therefor
EP0642786B1 (en) Method for the manufacture of a laxative composition
WO2005092293A1 (en) Formulations of metformin
US20030152621A1 (en) Pharmaceutical formulation of gepirone for oral administration
US4515802A (en) Analgesic preparations
AU2005235237A1 (en) Clarithromycin extended release formulation
EP0950419B1 (en) A solid preparation and a method of manufacturing it
JP2003534371A (ja) ２’−デオキシ−２’−（フルオロメチレン）シチジンの薬学的組成物
EP0973508A1 (en) Pharmaceutical tablet of amiodarone salt
CN108721241A (zh) 一种包含缬沙坦和氨氯地平的固体组合物及其制备方法
KR20050010843A (ko) 활성 성분을 지속 방출시키는, 옥스카바제핀 함유약제학적 조성물